Astrazeneca Stock News

A COVID-19 antibody drug developed by AstraZeneca is more than 80 per cent effective in cutting the risk of contracting symptomatic illness, the company says.

A COVID-19 antibody drug developed by AstraZeneca is more than 80 per cent effective in cutting the risk of contracting symptomatic illness, the company says.

AstraZeneca PLC (LSE:AZN) said new data from two COVID-19 Phase III trials has confirmed that its AZD7442 therapy provides protection against severe disease and death in high-risk populations. The tri

ASTRAZENECA has released the stunning results from its trial of a new coronavirus antibody therapy drug, showing it is 88 percent effective when given within three days of first symptoms.

AstraZeneca said on Thursday its COVID-19 antibody drug was 83% effective in cutting the risk of people contracting symptomatic illness in a six-month follow-up study, cementing the drugmakers lead in developing preventative coronavirus treatments. The Anglo-Swedish company said a separate study in patients with mild-to-moderate COVID-19 showed that a higher dose of the therapy, AZD7442, []

AstraZeneca Plc (NASDAQ: AZN) has shared new data from two Phase 3 trials of AZD7442, its long-acting antibody (LAAB) combination, in COVID-19 patients. In an analysis of the ongoing PROVENT trial

When administered to individuals who hadn't been exposed to Covid-19, the drug completely eliminated the risk of severe disease or death, the drugmaker said.

AstraZeneca's antibody treatment has been shown to be highly effective at preventing Covid in people who may not respond well to vaccines.

AstraZeneca PLC said Thursday that Phase 3 trials on its AZD7442 antibody combination confirmed that the treatment reduces risk of developing symptomatic Covid-19.

Freedman Financial Associates Inc. increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 149.3% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 733 shares of the company’s stock after purchasing an additional 439 shares during the period. Freedman Financial Associates Inc.’s holdings in AstraZeneca were worth […]

Fragasso Group Inc. acquired a new position in AstraZeneca PLC (NASDAQ:AZN) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 17,107 shares of the companys stock, valued at approximately $1,027,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Activest Wealth Management bought a []

Veriti Management LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 81.4% during the third quarter, Holdings Channel reports. The fund owned 31,683 shares of the companys stock after purchasing an additional 14,218 shares during the quarter. Veriti Management LLCs holdings in AstraZeneca were worth $1,903,000 at the end of the most recent []

This includes anyone 70 and older. those who got a double dose of AstraZeneca and frontline healthcare workers who had less than 28 days between their first and second doses